Materials for the media and investors

The Synektik Group are the leading manufacturer of the advanced radiopharmaceutical products and IT solutions (such as tele-radiological platform “Zbadani.pl”), provide maintenance and measurement services and are a distributor of innovative medical devices for diagnostics and therapy in the fields of oncology, cardiology, neurology and radiology.

As part of the medical equipment and IT solutions sales, along with the service activities, the Group also:

• cooperate with several global manufacturers of diagnostic and therapeutic products.
  As part of this activity, the Group provide comprehensive equipment delivery, combined with the preparation of necessary premises, installation of equipment, service and staff training.
  Thanks to their broad product portfolio and acquired competences, the company offer, among others, construction of hybrid operating rooms on a turnkey basis;
• have their own IT solutions for archiving, distribution, presentation and processing of radiological images and administrative data. The proprietary project of the tele-radiology platform Zbadani.pl offers a range of innovative e-services for medical facilities, doctors and patients.  In addition, the Group offers classic IT solutions dedicated to radiology.  The ArPACS product family enables computerization of healthcare entities in the field of archiving, distribution (PACS), presentation and processing of radiological images (ArView) and administrative data (RIS);
• offer servicing of selected products from the medical equipment offered. Acceptance and specialist tests are performed in the imaging diagnostics equipment research laboratory run by the Dominant Entity, which is accredited by the Polish Accreditation Centre.

Within the radiopharmaceuticals segment, Synektik have three production plants in Poland, one of which serves as a research and development centre for the development of new, innovative products for use in oncology, cardiology and neurology.  The group are also developing their own clinical research centre.  The company remain the leading supplier of specialty radiopharmaceuticals in Poland, used, among others, for the diagnosis of hepatocellular or prostate cancer and its bone metastases.

The Company’s flagship project is a cardiotracer – an innovative radiopharmaceutical with global potential for diagnosing coronary heart disease, the development of which is currently at the clinical trial stage.

The basic parameter determining the financial results in individual areas of the Capital Group’s operations is the volume of sales of services and products.  In the case of the IT solutions sales and equipment supplies segment, it is primarily the number of orders from hospitals and other medical facilities and the profitability of concluded contracts, which depends on a number of factors influencing the scope of the offer (assortment, costs of the room adaptation process, etc.).  In the case of the radiopharmaceutical production segment, the range of products supplied (basic radiopharmaceuticals vs. specialty radiopharmaceuticals) and supply logistics have a significant impact on the results.

Synektik operate primarily in Poland and neighbouring countries (Czech Republic, Slovakia, Baltic republics).  In the future – mostly due to the introduction of new radiopharmaceutical products, including an innovative cardiotracer – the Group plan to enter other markets, mainly in Europe and the United States.

The Company’s market share varies depending on the segment of their operations, and their position is at the forefront or among the 2-4 leading companies operating in a given area.  In the case of both – radiopharmaceutical production and measurement activities, we are the largest entity operating on the domestic market, with three production plants and serving the largest number of medical centers. As far as measurement activities are concerned, we perform about 2.5 thousand tests per year and for over ten years have been a leader in Poland.  Our IT solutions are among the 3-4 most frequently chosen IT systems used in radiology.

Synektik actively take advantage of the opportunity to obtain grants to finance their innovative projects.  By the end of 2017, over PLN 30 million had been raised in this way.  One of the projects most supported by public funds is the cardiotracer, i.e. a special radiopharmaceutical used in the diagnosis of coronary artery disease.  In 2015, the Group received approximately PLN 15.7 million in non-contributory subsidies from the prestigious EU Horizon 2020 programme to implement this project.

The cardiotracer is currently in clinical trials.

Over the next few years, the Management Board will apply for the payment of dividends depending on the Company financial situation as well as the general market situation.  In previous years, the entire net profit generated by the company was allocated to reserve capital.  On March 3, 2020, Synektik Annual General Meeting decided to pay the first dividend in the Company’s history in the amount of PLN 3.07 million, i.e. PLN 0.36 per share.

The leading positions in the global radiopharmaceuticals market are occupied by, among others, GE Healthcare, Amersham, Siemens (Petnet), Cardinal Health and Bayer.  Companies operating in Europe with a similar profile to Synektik include, for example, the French AAA (taken over by Novartis) and the German Eckert & Ziegler.  Comparable entities on the Polish radiopharmaceuticals market are Voxel and Life Radiopharma.  In the segment of medical equipment supplies and maintenance services, the Company compete with both distributors and equipment manufacturers operating directly in Poland.